These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31259160)

  • 1. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.
    Telatin V; Nicoli F; Frasson C; Menegotto N; Barbaro F; Castelli E; Erne E; Palù G; Caputo A
    Front Cell Infect Microbiol; 2019; 9():190. PubMed ID: 31259160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of direct-acting antiviral agents on the frequency of myeloid-derived suppressor cells and natural killer cells in patients with chronic hepatitis C.
    Li Y; Zeng Y; Zeng G; Li J; Zhang X; Cai Q; Chen Y; Lin CS
    J Med Virol; 2019 Feb; 91(2):278-286. PubMed ID: 30171691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons.
    Auma AWN; Shive CL; Lange A; Damjanovska S; Kowal C; Zebrowski E; Pandiyan P; Wilson B; Kalayjian RC; Canaday DH; Anthony DD
    Front Immunol; 2021; 12():641230. PubMed ID: 33912168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
    J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
    Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
    Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral PD-1
    Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
    Front Immunol; 2019; 10():1470. PubMed ID: 31316516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Early Viral Control under Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus Using Pretreatment Immunological Markers.
    Hutchinson JA; Weigand K; Adenugba A; Kronenberg K; Haarer J; Zeman F; Riquelme P; Hornung M; Ahrens N; Schlitt HJ; Geissler EK; Werner JM
    Front Immunol; 2018; 9():146. PubMed ID: 29467758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
    Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
    J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    Llorens-Revull M; Costafreda MI; Rico A; Guerrero-Murillo M; Soria ME; Píriz-Ruzo S; Vargas-Accarino E; Gabriel-Medina P; Rodríguez-Frías F; Riveiro-Barciela M; Perales C; Quer J; Sauleda S; Esteban JI; Bes M
    PLoS One; 2021; 16(7):e0254243. PubMed ID: 34242330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.
    Auma AWN; Shive CL; Kostadinova L; Anthony DD
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection.
    Han JW; Sung PS; Kim KH; Hong SH; Shin EC; Jun Song M; Park SH
    J Infect Dis; 2019 Sep; 220(8):1290-1301. PubMed ID: 31152667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8
    Vranjkovic A; Deonarine F; Kaka S; Angel JB; Cooper CL; Crawley AM
    Front Immunol; 2019; 10():1926. PubMed ID: 31456810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals.
    Kim SY; Koh JY; Lee DH; Kim HD; Choi SJ; Ko YY; Lee HS; Lee JS; Choi IA; Lee EY; Jeong HW; Jung MK; Park SH; Park JY; Kim W; Shin EC
    J Hepatol; 2024 Nov; 81(5):806-818. PubMed ID: 38879170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
    Burchill MA; Golden-Mason L; Wind-Rotolo M; Rosen HR
    J Viral Hepat; 2015 Dec; 22(12):983-91. PubMed ID: 26482547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Pillai V; Lee WM; Thiele DL; Karandikar NJ
    J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYELOID-DERIVED SUPPRESSOR CELLS TWO YEARS AFTER HEPATITIS C VIRUS ERADICATION USING DIRECTLY ACTING ANTIVIRALS.
    Abunawas D; Abbasy A; Afifi M; Moaaz M; Kamal A; Awaad A; Elsherbini B
    Arq Gastroenterol; 2024; 61():e24004. PubMed ID: 39046003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
    Han JW; Sung PS; Hong SH; Lee H; Koh JY; Lee H; White S; Maslow JN; Weiner DB; Park SH; Jeong M; Heo J; Ahn SH; Shin EC
    J Hepatol; 2020 Jul; 73(1):72-83. PubMed ID: 32088322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients.
    Zeng QL; Yang B; Sun HQ; Feng GH; Jin L; Zou ZS; Zhang Z; Zhang JY; Wang FS
    Mol Cells; 2014 Jan; 37(1):66-73. PubMed ID: 24552712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.